FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape

BACKGROUND. With the exception of trastuzumab, therapies directed at receptor tyrosine kinases (RTKs) in gastroesophageal adenocarcinomas (GEA) have had limited success. Recurrent fibroblast growth factor receptor 2 (FGFR2) alterations exist in GEA; however, little is known about the genomic landsca...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncologist
Prif Awduron: Klempner, Samuel J., Madison, Russell, Pujara, Vivek, Ross, Jeffrey S., Miller, Vincent A., Ali, Siraj M., Schrock, Alexa B., Kim, Seung Tae, Maron, Steven B., Dayyani, Farshid, Catenacci, Daniel V.T., Lee, Jeeyun, Chao, Joseph
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley & Sons, Inc. 2019
Pynciau:
Gastrointestinal Cancer
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853122/
https://ncbi.nlm.nih.gov/pubmed/31249137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0121
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg